At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 104 enrolled
Drug / intervention
Pasireotide sub-cutaneousdrug
Likely dose
Pasireotide sub-cutaneous 1 mlfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease (Seascape).
In Brief
A Phase 3 clinical trial evaluating Pasireotide sub-cutaneous for Cushing's Disease. Completed, enrolled 104 participants across 65 sites in 11 countries.
Detailed Summary
This study provided access to pasireotide sc in patients with Cushing's disease.and provided additional information for safety and efficacy of pasireotide s.c.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCushing's Disease
CountriesBrazil, Czechia, Germany, Greece, Lebanon, Romania, Russia, South Korea, Spain, Thailand, United States
Collaborators--
Timeline
Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartAug 2011
First PostedApr 2012
Primary CompletionJan 2017
TodayJul 2026
First PostedApr 20, 2012
Enrollment StartAug 16, 2011
Primary CompletionJan 26, 2017
TodayJul 2, 2026
Enrollment to primary: 5.4 yearsPosted 14.2 years ago
Interventions
Pasireotide sub-cutaneousdrug
Pasireotide sub-cutaneous was supplied in 1 ml ampoules containing 900 μg, 600 μg, or 300 μg pasireotide per 1 ml of solution and was administered BID. Starting dose was 900 μg and 600 μg for glucose impaired metabolism patients